BLI Combinations

Farmentin ES

Co-Amoxiclav

Each measure (5ml) contains: Amoxicillin (as trihydrate) 600 mg, Clavulanic acid (as potassium) 42.9 mg

Powder for oral suspension

Dosage form

643 mg/5 ml

Dose

Powder for 75 ml oral suspension; Powder for 100 ml oral suspension

Pack

Rx

Farmentin ES 643 suspension
DOSAGE FORMS

Doses & Packs

643 mg/5 ml (Suspension)

Farmentin ES 643 suspension
Clinical information

Usage guide

WARNINGS

Warnings & precautions

  • Twice daily
  • Shake well before use
STORAGE

Storage conditions

  • Store in a dry place, below 25°C
  • Reconstituted suspension must be stored in refrigerator and used within 7 days (100 ml box: within 10 days).
  • Keep from freezing

Dosage Forms

  • Farmentin ES-643 powder for oral suspension, after reconstitution each measure (5ml) contains 600 mg amoxicillin and 42.9 mg Clavulanic acid (as potassium).

Drug Group

Antibiotic, Beta-lactam + Beta-lactamase inhibitor

Packaging

  • Powder for 75 ml oral suspension.

Farmentin ES-643 is given by mouth in the treatment of bacterial infections of lower respiratory tract, otitis media, sinusitis, skin and skin structure infections, urinary tract infections, chancroid and gonorrhea

Farmentin ES-643 is an oral antibacterial combination consisting of the semisynthetic antibiotic amoxicillin and the β-lactamase inhibitor, clavulanate potassium (the potassium salt of clavulanic acid). Betalactam antibiotic that inhibits the biosynthesis of cell wall of bacteria. Clavulanic acid has a high affinity for and binds to certain betalactamases that generally inactivate amoxicillin. Farmentin ES-643 is active against H. influenzae, M. catarrhalis, S. aureus, E. coli, Klebsiella sp. and Entrobacter sp.

Farmentin ES-643 is not indicated in history of hypersensitivity to penicillins, cephalosporins, imipenem and betalactamase inhibitors. Farmentin ES-643 should be used with caution in patients with evidence of hepatic dysfunction and history of GI diseases especially antibiotic-associated colitis. In renal impairment, reduction in dosage or increase in dosing interval is recommended. The suspensions contain aspartame and should not be used by phenylketonurics. Farmentin ES-643 in patients with infectious mononucleosis should not be used.

Diarrhea, hepatitis, cholestatic jaundice, pseudomembranous colitis, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis and exfoliative dermatitis have been reported.

Farmentin ES-643 crosses the placenta. Use during pregnancy only if clearly needed. Small amounts of amoxicillin are distributed into breast milk. The use of Farmentin ES-643 may cause diarrhea, candidiasis or allergic response in the nursing infants.

Probenecid prolongs the half-life of amoxicillin. Amoxicillin may also interact with bacteriostatic antibacterials. Co-Amoxiclav may reduce the efficacy of oral contraceptives. Concomitant use of allopurinol and amoxicillin should be avoided. Increases in prothrombin time have been reported in patients taking Co-Amoxiclav concurrently with anticoagulants. False-positive urine glucose reactions may occur in non-enzymatic tests using cupric sulfate in penicillin therapy.

AT A GLANCE

Pack details

Scroll to Top